替格瑞洛单药治疗急性冠脉综合征:TICO与T-PASS试验个体患者数据Meta分析
该研究汇总TICO和T-PASS两项随机试验的5906例ACS患者个体数据,比较短期DAPT后替格瑞洛单药与替格瑞洛为基础12个月DAPT。
要点
- ACS患者DES植入后,短期DAPT后替格瑞洛单药不增加缺血事件。
- 替格瑞洛单药较替格瑞洛为基础12个月DAPT显著减少大出血。
- 结论在纳入ACS亚组的汇总数据Meta分析中一致。
核心结论
- ACS患者DES植入后,短期DAPT后替格瑞洛单药较替格瑞洛为基础12个月DAPT减少大出血,且不增加缺血事件。
研究设计与样本
- 电子数据库检索至2023年11月11日,主要分析汇总比较短期(≤3个月)DAPT后替格瑞洛单药与替格瑞洛为基础12个月DAPT的随机临床试验个体患者数据,仅限ACS行DES植入患者。
- 纳入两项随机临床试验共5906例ACS患者。
主要发现
- 纳入ACS亚组的汇总数据二次Meta分析结果一致。
关键数值与推荐
- 主要缺血终点:全因死亡、心肌梗死或卒中复合终点,1年时评估。
- 主要出血终点:BARC 3或5型出血,1年时评估。
- 短期DAPT定义为≤3个月。
临床怎么用
- ACS患者DES植入后,可考虑短期DAPT后转为替格瑞洛单药,以降低出血风险而不增加缺血事件。
局限性
- 主要分析仅基于两项随机临床试验的个体患者数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In patients with acute coronary syndrome (ACS), dual antiplatelet therapy (DAPT) with aspirin and a potent P2Y12 inhibitor is recommended for 12 months after drug-eluting stent (DES) implantation. Monotherapy with a potent P2Y12 inhibitor after short-term DAPT is an attractive option to better balance the risks of ischaemia and bleeding. Therefore, this study evaluated the efficacy and safety of ticagrelor monotherapy after short-term DAPT, especially in patients with ACS. METHODS: Electronic databases were searched from inception to 11 November 2023, and for the primary analysis, individual patient data were pooled from the relevant randomized clinical trials comparing ticagrelor monotherapy after short-term (≤3 months) DAPT with ticagrelor-based 12-month DAPT, exclusively in ACS patients undergoing DES implantation. The co-primary endpoints were ischaemic endpoint (composite of all-cause death, myocardial infarction, or stroke) and bleeding endpoint [Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding] at 1 year. RESULTS: Individual patient data from two randomized clinical trials including 5906 ACS patients were analysed. At 1 year, the primary ischaemic endpoint did not differ between the ticagrelor monotherapy and ticagrelor-based DAPT groups [1.9% vs. 2.5%; adjusted hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.56-1.13; P = .194]. The incidence of the primary bleeding endpoint was lower in the ticagrelor monotherapy group (2.4% vs. 4.5%; adjusted HR 0.54; 95% CI 0.40-0.72; P < .001). The results were consistent in a secondary aggregate data meta-analysis including the ACS subgroup of additional randomized clinical trials which enrolled patients with ACS as well as chronic coronary syndrome. CONCLUSIONS: In ACS patients undergoing DES implantation, ticagrelor monotherapy after short-term DAPT was associated with less major bleeding without a concomitant increase in ischaemic events compared with ticagrelor-based 12-month DAPT. STUDY REGISTRATION: PROSPERO (ID: CRD42023476470).
引用
- Lee, Shin, Kwon, et al. Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trials. Eur Heart J. 2024. PMID: 38750627. doi:10.1093/eurheartj/ehae249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。